Hims & Hers stock tumbled in early action on Monday after the U.S. company quickly reversed plans to introduce its own version of Novo Nordisk’s Wegovy oral weight-loss drug.
Trending
- Hong Kong fire victims long for home as Lunar New Year stirs painful memories
- Top Democrat slams GOP voter ID, citizenship bill as voter suppression
- ‘Marty Supreme’ Gets China Date; Movie To Be A24’s Highest Grossing
- Patrick Reed battling back his own way through barrage on DP World Tour
- Waymo is testing driverless robotaxis in Nashville
- Super Bowl winner Sam Darnold just made another $2.5 million on Sunday
- Rep. Raja Krishnamoorthi, D-Ill., talks abut the deposition of Ghislaine Maxwell : NPR
- Iran crackdown widens to ensnare reformist figures : NPR
Tuesday, February 10
Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor
